Pediatric rheumatology

Comparison of EULAR/PRINTO/Pediatric Rheumatology European Society (PReS) Ankara 2008 and 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis in children

Rheumatology (Oxford)Published Diagnostic accuracy study

Authors' conclusion

In children, both the ACR/EULAR and EULAR/PRINTO/PReS Ankara 2008 classification criteria for GPA perform well and similarly.

Study context

Population
Paediatric patients with granulomatosis with polyangiitis (GPA) (diagnosis by expert opinion) and controls with other vasculitides, 20 centres in 9 countries77 GPA, 108 controls
Comparison
2022 ACR/EULAR vs EULAR/PRINTO/PReS Ankara 2008 classification criteria for GPA
Outcome
Sensitivity, specificity, PPV and NPV of the criteria sets
Methodological detailsretrospective, multicentre (20 centres, 9 countries)
  • Retrospective
  • Multicentre (20 centres, 9 countries)

Performance

As reported in the abstract

Performance of classification criteria for GPA
Test or modelValueSensitivitySpecificity
Ankara 2008 criteria73 events94.8%95.3%
ACR/EULAR classification criteria69 events89.6%96.3%

Value

Ankara 2008 criteria73 events
ACR/EULAR classification criteria69 events

Sensitivity

Ankara 2008 criteria94.8%
ACR/EULAR classification criteria89.6%

Specificity

Ankara 2008 criteria95.3%
ACR/EULAR classification criteria96.3%
  • ACR/EULAR classification criteria vs Ankara 2008 criteria: P = 0.229 — No significant difference
  • ACR/EULAR classification criteria vs Ankara 2008 criteria: P = 0.733 — No significant difference

Further findings

Most common presentations in GPA

Constitutional symptoms
85.7%
ENT involvement
79.2%

Original publication

Comparison of EULAR/PRINTO/PReS Ankara 2008 and 2022 ACR/EULAR classification criteria for granulomatosis with polyangiitis in children. Rheumatology (Oxford). Published 22 December 2023. doi:10.1093/rheumatology/kead693

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.